Doctors closing door on oncology drug reps
Targeted cancer drugs are one of the great hopes for pharmaceutical companies, but a business survey says cancer doctors are limiting visits by sales representatives more than most medical specialists. Whether this is good or bad depends, of course, on your perspective or how you make money. ZS Associates, a global sales and marketing firm, published its spring 2012 AccessMonitor report this week and it says about 61 percent of oncologists placed moderate-to-severe restrictions on visits from pharmaceutical sales reps. The report says oncologists were the most restrictive of the 20 most common medical specialties measured. About 47 percent of cardiologists and 38 percent of primary care physicians restricted sales representative access to the same degree, according to the report.
- How Top-Ranked MA Plans Earn Their Stars
- How Hospitals Can Become 'Upstreamists'
- Readmissions: No Quick Fix to Costly Hospital Challenge
- WellPoint Dominates Nearly Half of Markets, AMA Says
- CMS Offers Some ACOs $114M for 'Upfront' Costs
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- 4 Tips for Managing Employed Physicians
- Ebola: Second TX Nurse Diagnosed After Improper Protective Gear Application
- House Calls Key to Pioneer ACO Success
- Providers Ask HHS to Address EHR Interoperability Barriers